This study measured urinary excretion and renal levels of hepatocyte growth factor (HGF) in children with Henoch-Schönlein purpura (HSP), examining the relationship between HGF, proteinuria and renal pathological changes. Seventy-eight patients with HSP aged 6 -18 years were divided into three groups, based on urinary albumin excretion rate. Urinary HGF concentration was measured by enzyme-linked immunosorbent assay. Renal biopsies were performed in 22 patients; renal levels of HGF protein were determined immunohistochemically. Compared with controls, urinary HGF was significantly increased in patients with normoalbuminuria and microalbuminuria, especially in those with microalbuminuria; no differences were observed between patients with macroalbuminuria and controls. Little or no HGF was present in normal kidney, but HGF was present in renal tissue in all HSP patients, particularly those with microalbuminuria. Urinary HGF was strongly correlated with the presence of renal HGF. These results suggest that HGF is associated with proteinuria and renal pathological changes in children with HSP. The detection of urinary HGF in children with HSP may be a non-invasive, effective, method for early diagnosis of renal injury.
Introduction
Henoch-Schönlein purpura (HSP) is a systemic abnormal reactive vasculitis that occurs most frequently around school age; renal failure induced by progressive HSP nephritis (HSPN) is the primary cause of the associated mortality. 1, 2 In long-term followup studies, it has been reported that 21 -33% of patients with HSPN progress to endstage renal disease. 3, 4 The exact pathogenesis of HSPN remains unclear, although excessive deposition of extracellular matrix (ECM) in the mesangial region is a key pathological feature. 5 Hepatocyte growth factor (HGF) is a potent renotropic factor that modulates the production and degradation of ECM in various renal diseases. 6 -8 The role of HGF in children with HSPN remains, however, largely unknown.
URINARY ASSAY
A 24-h urine sample was obtained from each study participant and the total volume was recorded. The sample was then centrifuged at 357.76 g for 10 min and 2 ml of supernatant was removed and stored at -80°C until analysis.
The urinary albumin concentration was determined using a radioimmunoassay and the urinary albumin excretion rate (UAER) was calculated using the 24-h urine volume. Patients were divided into three groups based on the UAER in the acute phase of HSP: the normoalbuminuria group included those with a normal UAER < 20 µg/min; the microalbuminuria group included those with a UAER between 20 and 200 µg/min; the macroalbuminuria group included those with a UAER > 200 µg/min. Urinary HGF concentrations were measured using an enzyme-linked immunosorbent assay kit (Westang, Shanghai, China) according to the manufacturer's instructions. Briefly, antihuman HGF monoclonal antibody was used as the capture antibody and biotinylated polyclonal antibody was used as the detection antibody. The urinary HGF level was expressed as a ratio relative to the urinary creatinine level in order to eliminate the effect of urine concentration.
HISTOLOGICAL AND IMMUNOHISTOCHEMICAL EVALUATION
Paraffin sections, 2 -3 µm thick, were prepared from renal tissue, stained with haematoxylin and eosin (H&E), and observed using a light microscope. In addition, immunohistochemical analysis of HGF was performed on the paraffin sections using an enzyme-labelled indirect method. 9 Rabbit antihuman HGF monoclonal antibody (1:80 dilution; Boster Biological Technology, Wuhan, China) was used as the primary antibody and biotin-labelled goat antirabbit immunoglobulin G (Boster Biological Technology) was used as the secondary antibody. Endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide in methanol for 30 min at 37°C. After being washed in 20 mM phosphate-buffered saline (PBS), pH 7.2 -7.6, the sections were incubated at 4°C overnight with the primary W Ding, S Sun, J Zhen et al. Hepatocyte growth factor in children with Henoch-Schönlein purpura antibody, washed again with 20 mM PBS, and incubated at 37°C for 20 min with the secondary antibody. Finally, after being washed with 20 mM PBS, the sections were treated with 3,3′-diaminobenzidine tetrachloride (Boster Biological Technology) to develop the colour reaction before H&E staining. As a negative control, the primary antibody was replaced by PBS. Immunohistochemical data were analysed using Image-Pro Plus (Media Cybernetics, Silver Spring, MD, USA) and expressed as the integral optical density (IOD).
STATISTICAL ANALYSES
All data are expressed as mean ± SD. All analyses were performed using the SPSS ® statistical package, version 16.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Differences between the control group and patient groups were evaluated using one-way analysis of variance with Fisher's post hoc comparison. To reduce the heterogeneity of variance, all the data were logarithmically transformed for statistical analysis. Linear correlation analysis was performed to quantify the association between urinary HGF level and renal HGF. A P-value < 0.05 was considered to be statistically significant.
Results

PATIENTS
Seventy-eight patients (27 females and 51 males) aged 6 -18 years (mean 8.2 years) with HSP were included in the study. In addition, 26 healthy children aged 6 -18 years were recruited as controls ( Table 1 ). All 78 patients had typical cutaneous manifestations of HSP: 14 had joint symptoms, 29 had gastrointestinal involvement and 40 had renal involvement with haematuria (> 3 red blood cells in urinary sediment per high-power field) and/or proteinuria (UAER > 20 µg/min).
Overall, 38 patients had normoalbuminuria, 24 had microalbuminuria and 16 had macroalbuminuria. Twenty-two patients underwent renal biopsy in the acute phase, including five children with normoalbuminuria, nine children with microalbuminuria and eight with macroalbuminuria.
URINARY HGF LEVEL
As shown in Table 1 , urinary HGF levels were significantly increased in patients with normoalbuminuria (P < 0.05) or microalbuminuria (P < 0.01) compared with the control group. In addition, HGF levels were significantly higher in the microalbuminuria group than in the normoalbuminuria group (P < 0.01). Urinary HGF was significantly lower in patients with macroalbuminuria, compared with those with normoalbuminuria or microalbuminuria (P < 0.01). Although urinary HGF levels in patients with macroalbuminuria were lower than levels in the control group, this difference was not statistically significant.
RENAL PATHOLOGY
The pathological diagnosis in all 22 renal biopsies from children with HSP was HSPN. According to the International Study of Kidney Disease in Children (ISKDC) classification for HSPN, 10 the normoalbuminuria group consisted of one patient with stage I and four patients with stage IIa, the microalbuminuria group consisted of two patients with stage IIa, four patients with stage IIb and three patients with stage IIIa, and the macroalbuminuria group consisted of two patients with stage IIIa and six patients with stage IIIb disease ( Fig. 1 ).
RENAL HGF EXPRESSION
Positive HGF staining was seen as a brown W Ding, S Sun, J Zhen et al. Hepatocyte growth factor in children with Henoch-Schönlein purpura colouration. Little or no HGF protein could be seen in the normal controls, but HGF protein was clearly present in the renal tissues in all the HSP patients. As shown in Fig. 2 , the IOD for HGF staining was significantly higher in the microalbuminuria group than in both the normoalbuminuria and macroalbuminuria groups (P < 0.05). There was no statistically significant difference in IOD between the normoalbuminuria group and the macroalbuminuria group. HGF staining was mainly seen in the cytoplasm and was much more pronounced in the renal tubular epithelial cells; little staining was observed in the glomerular epithelial cells and mesangial cells ( Fig. 3 ).
CORRELATION BETWEEN URINARY HGF LEVEL AND RENAL HGF EXPRESSION
Linear correlation analysis (Fig. 4) revealed a significantly positive correlation between the urinary HGF level and renal HGF expression (r = 0.704, P < 0.001).
Discussion
The present study showed that urinary HGF levels were increased in HSP patients with normoalbuminuria and microalbuminuria, but not in patients with macroalbuminuria. Moreover, little or no renal HGF protein was observed in the normal controls, but all patients with HSP clearly showed HGF immunostaining in renal tissues. The IOD of renal HGF staining was significantly higher in patients with microalbuminuria than in those with normoalbuminuria or macroalbuminuria. In addition, there was a positive correlation between the urinary HGF level and renal HGF.
It is well known that HGF is a pleiotropic renal nutrition factor that possesses mitogenic, morphogenic, anti-apoptotic and W Ding, S Sun, J Zhen et al. Hepatocyte growth factor in children with Henoch-Schönlein purpura anti-inflammatory activities. 11 -13 In vivo and in vitro studies have demonstrated that HGF may protect against the development of renal fibrosis in various chronic renal diseases. 14 -17 There have, however, been few reports on whether HGF is involved in the development of renal injury in children with HSP. A renal biopsy and immunohistochemical study in children with HSPN showed that the average score for glomerular c-Met (the HGF receptor) staining in acutephase patients with crescent formation was significantly higher than in those without crescent formation. 18 Moreover, in a second biopsy taken after a mean (± SD) of 5.3 (± 2.2) months, the average score for c-Met staining in patients with a poor prognosis was lower than in those with a good prognosis. 18 Renal HGF levels were not, however, examined in that study.
It was demonstrated in the present study that the ISKDC stage on renal biopsy increased with the UAER. This suggests that the UAER reflects the severity of renal injury in patients with HSPN. 19 It was also found that little or no HGF staining could be detected in normal renal tissues, but staining was present in the renal tissues from all the patients with HSP. Renal HGF levels increased along with UAER in the early stages of HSP, but when the UAER had increased to the macroalbuminuria stage, renal HGF levels began to decrease, suggesting that HGF is probably involved in the development of HSPN. Several studies in animals and humans have demonstrated that, when the kidney is injured (especially in the early stages following trauma), HGF protein level increases to initiate antiinflammatory activity and promote tissue repair and regeneration. 20, 21 Consistent with this notion, the present study suggests that, at the initial stage of renal involvement in children with HSP, the production of HGF from the kidney increases to provide protection. As renal injury progresses, however, HGF production falls. The possible reasons for this may be as follows: (i) angiotensin II and transforming growth factor-β are produced after kidney injury and are strong negative growth factors that inhibit HGF expression; 22 (ii) interstitial cells producing HGF trans-differentiate into myofibroblasts that do not produce HGF during the process of renal fibrosis; 23 or (iii) when renal cells are severely damaged, they may lose the ability to secrete HGF. Renal HGF protein was mainly seen in the renal tubular epithelial cells, with only a little observed in glomerular epithelial cells and mesangial cells, but the reasons underlying this observation are unclear.
Nishida et al. 24, 25 reported that serum HGF levels were not elevated in patients with HSPN (eight patients with proteinuria > 0.5 g/day), but in patients with acute-phase HSP (14 patients, of whom three had renal involvement with microhaematuria and mild proteinuria), mean serum HGF levels were significantly higher than in the control group. These findings suggest that, when renal injury progresses further, serum HGF It is known that HGF is an extremely large molecule (molecular weight > 100 kDa), and it is unlikely to be removed by glomerular filtration. 26 Under normal conditions, the liver removes > 70% of HGF in circulation. 27, 28 Several studies in rats have indicated that < 5% of circulating HGF is cleared by the kidney. 29 When the kidney is injured there are two possible sources for urinary HGF: HGF circulating in the blood, and intrarenally produced. If HGF in the blood is the main source, HGF will pass into the urine along with other proteins, and the level of urinary HGF will increase with the UAER. In contrast, in the present study, urinary HGF was lower in patients with macroalbuminuria than in patients with normoalbuminuria or microalbuminuria, suggesting that when the kidney is injured, the HGF level in urine more accurately reflects HGF secretion from the kidney rather than the HGF level in the serum.
In addition, linear correlation analysis in the present study revealed a positive correlation between urinary HGF level and renal HGF, suggesting that the level of urinary HGF might reflect the level of renal HGF in HSP patients. The present study also showed that the level of urinary HGF was increased at a very early stage in patients with normoalbuminuria, indicating that the detection of urinary HGF in children with HSP may be a sensitive way to diagnose HSPN earlier than using UAER.
In conclusion, the present study demonstrated that HGF is associated with proteinuria and renal pathological changes in children with HSP. This association may reflect a role for HGF as a progression inhibitor in HSPN. Moreover, the detection of urinary HGF in children with HSP may be a non-invasive and effective method for the early diagnosis of renal injury. Further investigation is needed to address whether HGF can be used in the prevention and treatment of HSPN.
